神经外科医师大会系统综述与循证指南更新:神经病理学在成人进展性胶质母细胞瘤管理中的作用
该指南针对成人进展性或复发性胶质母细胞瘤,系统评价了IDH突变、MGMT启动子甲基化、EGFR扩增或突变、大panel或全基因组测序、免疫检查点生物标志物及贝伐珠单抗反应生物标志物检测的追加管理或预后信息价值,并给出相应推荐等级。
要点
- 若肿瘤组织学与原发肿瘤相似且临床过程符合预期,无需重复IDH突变检测(Level III)。
- 不推荐重复检测MGMT启动子甲基化(Level III)。
- 组织学难以分类为胶质母细胞瘤时,EGFR扩增检测有助于分类;若既往已检出EGFR扩增则无需重复检测。
核心结论
- 对于成人进展性胶质母细胞瘤,多数分子检测在特定条件下可提供追加信息,但重复IDH突变检测和重复MGMT启动子甲基化检测不必要或不推荐,PD-L1或错配修复酶活性不应作为标准检测组成部分,目前尚无基于本指南纳入标准的贝伐珠单抗反应生物标志物。
研究设计与样本
- 神经外科医师大会系统综述与循证指南更新,针对成人进展性或复发性胶质母细胞瘤患者。
主要发现
- 若肿瘤组织学与原发肿瘤相似且患者临床过程符合预期,重复IDH突变检测不必要(Level III)。
- 不推荐重复检测MGMT启动子甲基化(Level III)。
- 组织学难以分类为胶质母细胞瘤时,EGFR扩增检测可能有助于分类;若既往已检出EGFR扩增,重复检测不必要;考虑靶向治疗的患者可推荐重复EGFR扩增或突变检测(Level III)。
- 对于适合或有意愿接受分子引导治疗或临床试验的患者,可考虑原发或重复大panel或全基因组测序(Level III)。
- 当前证据不支持将PD-L1或错配修复酶活性作为标准检测组成部分(Level III)。
关键数值与推荐
- 重复IDH突变检测:Level III,若肿瘤组织学与原发肿瘤相似且临床过程符合预期则不必要。
- 重复MGMT启动子甲基化检测:Level III,不推荐。
- EGFR扩增检测:Level III,组织学难以分类时可能有助于分类;既往已检出扩增则无需重复;考虑靶向治疗时可推荐重复检测。
- 大panel或全基因组测序:Level III,可考虑用于适合或有意愿接受分子引导治疗或临床试验的患者。
- PD-L1或错配修复酶活性检测:Level III,当前证据不支持作为标准检测组成部分。
临床怎么用
- 对于进展性胶质母细胞瘤,若组织学与原发肿瘤相似且临床过程符合预期,无需重复IDH突变检测。
- 不推荐重复检测MGMT启动子甲基化。
- 组织学难以分类为胶质母细胞瘤时,可进行EGFR扩增检测以辅助分类;若既往已检出EGFR扩增则无需重复检测。
- 考虑靶向治疗的患者可推荐重复EGFR扩增或突变检测。
- 适合或有意愿接受分子引导治疗或临床试验的患者可考虑大panel或全基因组测序。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TARGET POPULATION: These recommendations apply to adult patients with progressive or recurrent glioblastoma (GBM). QUESTION: For adult patients with progressive glioblastoma does testing for Isocitrate Dehydrogenase (IDH) 1 or 2 mutations provide new additional management or prognostic information beyond that derived from the tumor at initial presentation? RECOMMENDATION: Level III: Repeat IDH mutation testing is not necessary if the tumor is histologically similar to the primary tumor and the patient's clinical course is as expected. QUESTION: For adult patients with progressive glioblastoma does repeat testing for MGMT promoter methylation provide new or additional management or prognostic information beyond that derived from the tumor at initial presentation and what methods of detection are optimal? RECOMMENDATION: Level III: Repeat MGMT promoter methylation is not recommended. QUESTION: For adult patients with progressive glioblastoma does EGFR amplification or mutation testing provide management or prognostic information beyond that provided by histologic analysis and if performed on previous tissue samples, does it need to be repeated? RECOMMENDATION: Level III: In cases that are difficult to classify as glioblastoma on histologic features EGFR amplification testing may help in classification. If a previous EGFR amplification was detected, repeat testing is not necessary. Repeat EGFR amplification or mutational testing may be recommended in patients in which target therapy is being considered. QUESTION: For adult patients with progressive glioblastoma does large panel or whole genome sequencing provide management or prognostic information beyond that derived from histologic analysis? RECOMMENDATION: Level III: Primary or repeat large panel or whole genome sequencing may be considered in patients who are eligible or interested in molecularly guided therapy or clinical trials. QUESTION: For adult patients with progressive glioblastoma should immune checkpoint biomarker testing be performed to provide management and prognostic information beyond that obtained from histologic analysis? RECOMMENDATION: Level III: The current evidence does not support making PD-L1 or mismatch repair (MMR) enzyme activity a component of standard testing. QUESTION: For adult patients with progressive glioblastoma are there meaningful biomarkers for bevacizumab responsiveness and does their assessment provide additional information for tumor management and prognosis beyond that learned by standard histologic analysis? RECOMMENDATION: Level III: No established Bevacizumab biomarkers are currently available based upon the inclusion criteria of this guideline.
引用
- Goodman AL, Velázquez Vega JE, Glenn C, et al. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of neuropathology in the management of progressive glioblastoma in adults. J Neurooncol. 2022. PMID: 35648306. doi:10.1007/s11060-022-04005-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。